PAM
XBIT icon

Paradigm Asset Management’s XBiotech XBIT Stock Holding History

Paradigm Asset Management’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-10,200
Closed -$213K – 789
2016
Q2 		$213K Buy
+10,200
New +$147K 0.04% 316

Other funds holding XBIT

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Paradigm Asset Management's XBIT Position: Q3 2016 in Review

Paradigm Asset Management sold out of XBiotech (XBIT) in Q3 2016, closing a stake of 10,200 shares — an estimated $213K sold.

Paradigm Asset Management first reported a position in XBIT in Q2 2016 and held it in 1 quarter. The position peaked at $213K in Q2 2016. 48 funds tracked by Wall St. Rank hold XBIT as of Q3 2016.

  • Paradigm Asset Management reported no remaining XBiotech position as of Q3 2016 after selling out during the quarter.
  • Paradigm Asset Management sold 10,200 XBiotech shares in Q3 2016, an estimated $213K.
  • Paradigm Asset Management first reported a position in XBiotech in Q2 2016 and held it in 1 quarter.
  • Paradigm Asset Management's XBiotech position peaked at $213K in Q2 2016.
  • 48 funds tracked by Wall St. Rank held XBiotech as of Q3 2016.

Based on Paradigm Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.